Biocracked
Approach 3, the human outcome, in palette B, warm.

Low three-quarter rear angle, shot with a 50mm lens at shallow depth of field. A middle-aged person's forearm and hand grip a loaded barbell mid-deadlift, the tendons and the muscle of the forearm clearly defined, with chalk dust hanging in the air. Their face is out of frame. The setting is a plain home garage gym with a rubber floor and a rack softly blurred in the background. Low golden-hour sunlight comes through an open roll-up door and rakes across the skin and the knurled steel, casting long warm shadows. Amber, copper and honey tones dominate, with matte black plates for contrast. A tiny electric green silicone wristband or a small green pen injector resting on a nearby shelf adds a subtle accent. The mood is determined, quiet and hopeful.
Metabolism

Tirzepatide 与阻力训练:举重可减少约1.1 kg 瘦组织流失

Rex Meridian · · 1 min read

Tirzepatide 与阻力训练:举重可减少约1.1 kg 瘦组织流失

Tirzepatide 在 40 周内可帮助减重超过 22 kg,但同时会带走一定的瘦组织和力量。最新的随机对照试验在 120 名超重或肥胖成年人中检验了每周三次阻力训练是否能改善这一现象。结果显示,脂肪减量保持不变,进行举重的受试者瘦软组织流失约少 1.1 kg;单药组力量下降,而举重组在所有测试中力量均有所提升。以下是数据细节以及对使用 Mounjaro 或 Zepbound 人群的启示。


Tirzepatide 在 40 周内可帮助减重超过 22 kg。若不进行阻力训练,其中约 4.7 kg 的减重来自瘦软组织,且力量出现倒退。每周三次的举重改变了这一局面。

该试验发表于 Nature Medicine(线上抢先出版,2026),是目前为止最直观的人体实验之一,专门检验阻力训练能否在基于 incretin 的减重过程中保护瘦组织。

实验设计:120 人,40 周,单药干预

西澳大学及合作机构招募了 120 名超重或肥胖的成年人,全部接受 tirzepatide。随后将受试者随机分为两组:

  • 仅 tirzepatide(T):保持日常活动不变
  • tirzepatide + 阻力训练(T+REx):每周三次阻力训练

干预持续 40 周。tirzepatide 的安全性良好,大多数参与者耐受最高 15 mg/周 的递增剂量。阻力训练的依从率为 91%。

本研究为人体随机对照试验,已在澳大利亚注册(ACTRN12623001236684),非动物或细胞实验。

关键数据

体重与脂肪减量:两组相当

阻力训练并未削弱药物的主要减重效果。

  • 体重减量:T = -22.61 kg vs T+REx = -22.28 kg (P = 0.694)
  • 总脂肪质量减量:T = -17.19 kg vs T+REx = -17.98 kg (P = 0.700)

两组之间的脂肪差异为 -0.77 kg(95% CI -2.14 至 0.60 kg),统计学上不具意义。

瘦组织:举重产生差异

  • 总瘦软组织质量:T = -4.67 kg vs T+REx = -3.57 kg (P < 0.001)
  • 组间差异:1.09 kg(95% CI 0.43 至 1.75 kg)
  • 四肢瘦软组织质量(手臂+腿):T = -3.55 kg vs T+REx = -2.92 kg (P < 0.001)

举重并未增加瘦组织,只是使流失量减少约四分之一。论文摘要将此效应描述为 “attenuation”,最为贴切。

力量:仅药物组下降,举重组上升

测试项目 仅 tirzepatide tirzepatide + 阻力训练
卧推 -4.09 kg +4.68 kg
背阔下拉 -4.42 kg +8.58 kg
膝伸展 -4.42 kg +5.88 kg

所有比较均达显著水平 (P < 0.001)。未进行训练时,上下半身力量均下降;进行训练时,各项指标均出现提升。

训练方案:摘要透露的要点

  • 频率:每周三次
  • 时长:40 周
  • 依从率:91%
  • 评估的肌群:卧推(上身推)、背阔下拉(上身拉)和膝伸展(下身)

摘要未给出每组的具体组数、次数、负荷或递进方式,这些细节应在全文中呈现,建议在制定具体方案前查阅全文。三项测试暗示了一个合理的模板:一次推、一种拉和一次腿部动作。

实际建议

  1. 每周安排三次阻力训练。这是本研究取得效果的频率,参与者的依从率达 91%。
  2. 覆盖全身。力量提升出现在推、拉和腿部练习,说明全身训练是可行方案。
  3. 目标是保留肌肉,而非一定要增肌。两组均出现瘦组织流失,举重组仅将流失量缩小约 1.1 kg。
  4. 脂肪减量不受影响。体重和脂肪减量在两组间无统计学差异。
  5. 保证足够的蛋白质摄入。虽然摘要未提及具体摄入量,但阻力训练期间的蛋白质补充仍是防止肌肉流失的常规建议,具体数值请咨询临床医生或营养师。
  6. 剂量由医生决定。大多数受试者最终达到了每周 15 mg,剂量的调整应遵医嘱,阻力训练并非决定剂量的依据。

适用人群

本研究对正在使用 tirzepatide(Mounjaro / Zepbound)的超重或肥胖成年人最具参考价值。对肌肉流失担忧较大的老年人尤其值得关注,因为他们的瘦组织本就偏少,更易出现无力和跌倒风险。摘要未提供受试者年龄分布或老年亚组分析,故无法直接确认结果在老年人中的适用性。老年人或有关节、心脏等基础疾病者应先咨询医生,并在专业教练指导下进行阻力训练。

注意事项

  • “瘦软组织”并非纯肌肉。它还包括体液和器官组织。力量提升说明功能受益,但该指标并非直接的肌肉量计数。
  • 仍会有部分瘦组织流失。举重组仍损失约 3.57 kg 瘦软组织,阻力训练只能减缓而非完全阻止流失。
  • 研究时长为 40 周。停药或停止训练后的长期效果尚未在摘要中讨论。
  • 利益冲突。多位作者报告了与制药公司(包括 Eli Lilly)之间的演讲酬劳或顾问关系,酬金均支付给西澳大学。其中一位作者是 ProGenis Pharmaceuticals 的股东及临床顾问。

结论

tirzepid​e 本身能够实现显著的体重和脂肪减量,但也会带走一定的瘦组织和力量。每周三次、持续 40 周的阻力训练可以在保持脂肪减量的同时,将瘦组织流失降低约 1.1 kg,并逆转力量下降。对于使用 GLP‑1 类药物的患者,本试验强烈建议将阻力训练纳入整体治疗方案。本文章仅供信息参考,非医疗建议。

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

RM

Written by

Rex Meridian

Rex Meridian writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: conceptual metaphor. Palette: D, bold color field.

A single steel dumbbell sits in the center of a saturated tomato-red seamless backdrop. A thick, taut rope of frayed tan fibers wraps around its handle, and a few strands are visibly thinning and unraveling at one end while the rest stay dense and intact, standing for muscle being preserved while weight drops. Shot at a low three-quarter angle with a shallow depth of field, so the knurled grip texture is crisp and the background melts into smooth red. Hard, directional studio light from the upper left casts a sharp, short shadow on the glossy red surface. One thin electric green cable tie is cinched around the rope. The mood is punchy, tense and editorial, with no people and no text.
peptides

怎样配合使用 Tirzepatide 才能保持肌肉?小鼠实验提供线索

BY NOVA CHEN ·

Tirzepatide 能快速减重,但肌肉会怎样?一项针对肥胖雌性小鼠的研究同时比较了药物单独使用、限时进食(TRF)以及阻力训练的效果。全套组合加速了体重和脂肪的下降,阻力训练保护了肌肉和力量,TRF 与 Tirzepatide 联合改善了葡萄糖耐受。肝脏的改善在所有干预中并无差异。该结果仅来自动物实验,不能直接套用于人类。

**Approach: Conceptual metaphor. Palette: D, bold color field.**

A single clear glass of water sits on a saturated mustard-yellow backdrop, shot at a slight low three-quarter angle. A hand-held pen injector rests beside it, its body a matte white with a small electric green dial ring as the only green accent. Hard but clean studio light from the upper left throws a crisp, defined shadow across the yellow surface. Through the glass, the injector is refracted into two slightly offset images, suggesting a signal that is split and hard to read. The mood is calm, questioning and balanced, with no drama. The background is fully warm and bright, with no blue cast. The surface has a subtle paper-like texture. There is no text, no label and no face.
metabolism

奥泽匹克(Ozempic)和蒙吉罗(Mounjaro)会导致抑郁吗?20项研究的发现

BY DR. SYNAPSE ·

奥泽匹克(Ozempic)和蒙吉罗(Mounjaro)会引发抑郁或自杀念头吗?最新对20项研究以及欧盟药品管理局(EMA)和美国食品药品监督管理局(FDA)的系统综述显示,迄今为止最有力的证据并未发现此类风险。包括两项2025年的大型荟萃分析在内的随机试验数据表明,使用赛马鲁肽(semaglutide)或替泽匹特(tirzepatide)并不增加自杀倾向、抑郁或焦虑的发生。令人担忧的信号主要来自于无法将药物效应与肥胖相关压力、基线精神风险以及报告偏倚区分开的研究设计。但由于临床试验普遍排除了精神疾病患者,仍需对高危人群和罕见的长期结局保持持续监测。

**Approach:** Lab in action. **Palette:** Bold color field, mustard yellow.

A close, slightly high three-quarter view of a hand in a magenta-purple nitrile glove holding a clear 12-well cell culture plate. Each well is filled with salmon-pink culture medium. A multichannel pipette hovers over one well, with a single droplet caught just before it falls. The background is a seamless, saturated mustard-yellow surface and wall, with a soft shadow under the plate. Bright, even studio light comes from the upper left, giving crisp highlights on the plastic rims and a soft glow through the liquid. The depth of field is shallow, so the far wells blur gently. A tiny electric-green cap on a tube sits in the corner of the frame. The mood is calm, precise and curious, with a clean, graphic, editorial feel. No text or labels.
peptides

赛马鲁肽未导致肌肉细胞萎缩,肌肉流失到底因何而起?

BY DR. SYNAPSE ·

最新《GeroScience》研究直接在肥胖老年人的原代人类肌管上测试赛马鲁肽和GIP,结果显示细胞既未激活萎缩基因,也未出现异常分泌蛋白,甚至在八天后肌纤维略有增厚。赛马鲁肽仅轻度抑制糖酵解产生的ATP,而GLP‑1受体几乎检测不到。这表明瘦体重的下降更可能源于热量赤字、蛋白质摄入不足和负荷降低等间接因素,而非药物本身对肌肉的直接毒性。

Approach: Macro science. Palette: B, warm.

Extreme macro photograph of a clear glass vial of blood plasma held in a gloved hand, shot at a slight low angle so the camera looks up through the tube. The plasma is cloudy and creamy at the top, where large fat-rich particles gather, and it clears to translucent golden amber toward the bottom, showing the drop in triglyceride particles. Tiny suspended droplets catch the light as bright specks. Warm honey-colored backlight from a low window-like source glows through the liquid and casts copper highlights across the glass. The background is a soft blur of warm brown and amber, with a faint electric green reflection on the rim of the vial cap. The mood is calm, precise and cautious, with a shallow depth of field and a real clinical texture on the glass. No text or labels.
metabolism

Retatrutide 将大颗粒甘油三酯降低 84%——但请先了解以下要点

BY DR. SYNAPSE ·

Retatrutide 最为人熟知的是它的减重效果,但两项 II 期试验的事后分析显示,它在血液指标方面同样表现惊人。在 2 型糖尿病患者中,大颗粒甘油三酯富含脂蛋白(TRL)最高下降 84.4%,而 ApoB 下降约 21%‑24%。在非糖尿病受试者中,高敏 C‑反应蛋白下降 54.8%,IL‑6 下降 29.6%,但这些变化在糖尿病组未达显著。该药尚未获批,仅为处方级研究药物,本文报道的仅是生物标志物的变化,并不等同于心血管事件风险的实际降低。

This page is available in